| Old Articles: <Older 24431-24440 Newer> |
|---|
 |
The Motley Fool
July 12, 2007
Nathan Parmelee |
Costco Cleans Up Some retailers are struggling, but Costco isn't one of them. If the markets hiccup at all during the second half of the year and Costco suffers, it should be high up on your list of positions to add to at around $50.   |
The Motley Fool
July 12, 2007
Mike Cianciolo |
American Eagle Takes Flight The retailer posts impressive comps growth and has updated its guidance. Investors, take note. |
The Motley Fool
July 12, 2007
Rick Aristotle Munarriz |
Hello, Welcome to Duller Image The techno gadgetry retailer Sharper Image has another rough month. After a few years of sandbagging, investors keep holding on to the hope that it won't take much to show an uptick in comps again. |
The Motley Fool
July 12, 2007
S.J. Caplan |
A HOG by Any Other Name The SEC approves ticker rules to increase competition and reduce confusion. |
The Motley Fool
July 12, 2007
Ryan Fuhrmann |
International Yumminess Chinese and other international sales continue to drive solid growth at Yum! Brands. The fast-food operator continues to reward investors. |
The Motley Fool
July 12, 2007 |
Yum! Goes Down Easy: Fool by Numbers The fast food operator released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 12, 2007
S.J. Caplan |
Stocks With Scruples Catch up with last month's developments in socially responsible investing. Calvert... Domini... A study by the Committee Encouraging Corporate Philanthropy found... etc. |
The Motley Fool
July 12, 2007
David Lee Smith |
Nothing Mini About This Bid In the latest in a string of steel company acquisitions, Gerdau Ameristeel will pay $86 a share for Chaparral Steel. Investors, take note. |
The Motley Fool
July 12, 2007
Emil Lee |
The Next Great Reinsurer? Flagstone Re has greatness in its DNA. Buying its shares could be a favorable risk-return proposition. |
The Motley Fool
July 12, 2007 |
Cancer Drugs Are the Key for Genentech: Fool by Numbers The large biopharma released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
| <Older 24431-24440 Newer> Return to current articles. |
